Adtran’s Coherent 100ZR and FSP 3000 OLS to play key role in OIF’s ECOC open interoperability showcase
20.9.2024 15:00:00 EEST | Business Wire | Press release
Adtran today announced its key role in the Optical Internetworking Forum’s (OIF) demonstration of open, multi-vendor networking at the European Conference on Optical Communication (ECOC) 2024. At the center of the showcase are Adtran’s Coherent 100ZR QSFP28 pluggable module and its FSP 3000 open optical line system (OLS), which enables the transport of a wide range of data rates, including 100ZR and 400Gbit/s OpenZR+, as featured in this demo. Incorporating 100Gbit/s to 800Gbit/s coherent pluggable transceivers and various OLS technologies from multiple vendors, the demo showcases advancements in open optical networking and innovative vendor-neutral solutions, highlighting the importance of testing multi-vendor interoperability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240920990844/en/
Adtran’s central role in the OIF demo underlines its commitment to developing open solutions that seamlessly interoperate with other vendors. (Photo: Business Wire)
“Adtran continues to lead the way in promoting open, disaggregated networking. By integrating our FSP 3000 OLS with 100ZR and 400Gbit/s OpenZR+ transceivers from a wide range of vendors, including our coherent 100ZR QSFP28, we’re offering operators a cost-effective, low-power solution to enhance their data center interconnect (DCI) networks and cloud infrastructure. With its standards-compliant design, our coherent 100ZR facilitates multi-vendor interoperability for 100Gbit/s transmission up to 300km over any open line system, while the FSP 3000 OLS streamlines operations and ensures flexible, scalable transport with optimal performance,” said Christoph Glingener, CTO of Adtran. “This collaboration with the OIF and other major industry players demonstrates our commitment to providing open solutions that meet the evolving demands of the cloud and the optical edge.”
The joint solution on display showcases exceptional optical performance, with the Adtran FSP 3000 OLS ensuring streamlined setup and precise operation. Equipped with integrated monitoring and diagnostic functions, as well as a high level of automation, the FSP 3000 OLS simplifies management and optimizes transmission performance. The collaboration with industry leaders highlights Adtran’s commitment to open optical networking solutions and demonstrates how its technology is built to industry standards. This approach offers the flexibility and scalability needed to meet diverse customer requirements while advancing multi-vendor interoperability.
“For decades, we’ve been pioneers in the DCI space, enabling enterprises and cloud providers to build high-capacity, high-performance networks. Our solutions are built around an open environment, promoting innovation and seamless interoperability with other vendors. We’re proud to be at the heart of this large-scale demonstration, where our Coherent 100ZR and FSP 3000 OLS are driving the adoption of open, multi-vendor interoperability for data center applications,” commented Stephan Neidlinger, VP of global business development at Adtran. “By championing openness and collaboration across the industry, we’re advancing high-performance networking and reaffirming our leadership in delivering the technologies that will shape the future of optical networking.”
Visitors to ECOC can find out more about the demo at Adtran’s booth, D79, and the OIF’s booth, B83.
OIF Champions Interoperability at ECOC 2024: 34 Member Companies to Showcase Solutions for Data Centers, AI/ML Technologies and Disaggregated Systems
At ECOC 2024, OIF will host a dynamic interoperability demonstration, featuring live collaboration from 34 member companies shaping the future of connectivity. This showcase will highlight advanced solutions that are redefining performance, efficiency and capacity in response to the burgeoning needs of future-oriented data centers, AI/ML technologies and disaggregated systems. Attendees will discover cutting-edge interoperability solutions in 800ZR, 400ZR and Multi-span optics, along with innovations in Energy Efficient Interfaces (EEI) & Co-Packaging, 224G and 112G Common Electrical I/O (CEI) and Common Management Interface Specification (CMIS) that are crucial for shaping the next decade of industry standards. Visit us at booth #B83 for live, interactive demonstrations. For further details, please visit: https://www.oiforum.com/meetings-events/oif-ecoc-2024.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240920990844/en/
Contacts
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Rhonda Lambert
+1 256 963 7450
investor.relations@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom